

## Case report

# Arrhythmogenic Right Ventricular Dysplasia Presenting With Sustained Ventricular Tachycardia: A Case Report And Review of Literature

### ABSTRACT

Arrhythmogenic right ventricular dysplasia (ARVD) is a cardiomyopathy characterized pathologically by fibrofatty tissue replacement of the myocyte of the right ventricle (RV) and clinically by life-threatening ventricular arrhythmias in young people. It is a major cause of sudden death. We present the case of a 60-year-old man with cardiovascular risk factors, who was admitted for hemodynamically unstable sustained ventricular tachycardia (VT) reduced by electrical cardioversion. After the stabilization of the patient, Electrocardiogram demonstrated an Epsilon wave in precordials and diffuse T-wave inversions. Transthoracic echocardiography revealed a dilated, hypokinetic right ventricle with moderately reduced function and a focal area of dyskinesia. The diagnosis of arrhythmogenic right ventricular dysplasia (ARVD) was made and an automatic implantable cardioverter defibrillator (ICD) was indicated for secondary prevention. This case report will present the clinical presentation, diagnosis and management of this rare disease.


**Key words:** Arrhythmogenic right ventricular dysplasia- Défibrillateur automatique implantable- sudden death.

## Introduction

Arrhythmogenic right ventricular Dysplasia (ARVD) is a hereditary genetic disease of the cardiac muscle; known also as Arrhythmogenic right ventricular cardiomyopathy (ARVC). It is a rare affection of the young adult[1]. It is one of the main causes of sudden death due to arrhythmia among young people and athletes. Its diagnosis is often difficult, based on a combination of clinical, electrical, morphological, and histological findings. Doppler Echocardiography is of considerable help in the study of morphological abnormalities. It remains the first-line examination to be requested in case of suspected ARVD.[2]


## Case report:

A 60-year-old man with cardiovascular risk factors such as chronic smoking at 15Pack years and dyslipidemia. He was admitted for hemodynamically unstable sustained ventricular tachycardia (VT); the mean ventricular rate was at 195 bpm with superior axis (Negative QRS in II, III, and aVF leads, and positive in aVL lead, midventricular inferior-septal location using the KUCCHAR algorithm [3]). A coronary angiography was performed excluding the ischemic etiology of the ventricular tachycardia.



**Figure1:** 12-lead electrocardiogram showing sustained Ventricular tachycardia.


After the stabilization of the patient by electrical cardioversion, the electrocardiogram showed a normal sinus rhythm at 50bpm, suspected epsilon waves in V2, V3, and V4, intraventricular block, and negative T waves in the anterior, lateral, and inferior territories.



**Figure 2:** 12-Lead electrocardiogram showing Epsilon waves in V2, V3, and V4 (blue arrows) and negative T waves in the anterior, lateral, and inferior territories (grey arrows).

Tr6f


Patterns of epsilon waves identified at the F-EKG realised to our patient was wiggle waves pattern in the FIII lead, and small spike waves pattern in FI and FII lead (Figure 3).




**Figure3:** Fontaine bipolar precordial leads (F-ECG).Pattern of the epsilon Waves:

Wiggle waves in FIII lead (yellow arrow) and small spike waves in FI and FII lead(green arrow).




Transthoracic echocardiography revealed moderate dilation of the Right ventricle(RV), depressed RV systolic function with segmental kinetic disorders as anterior wall akinesia; lateral wall and apex hypokinesia (**Figure 4**). However, the left ventricle size and systolic function were preserved.





**Figure 4:** (4a) Apical Four -chamber view showing apical trabeculations. (4b) Apical four-chamber and (4c) Parasternal long axis echocardiographic view (PLAX) showing RV dilatation.

24-Hour Holter Monitoring showed basic sinus rhythm. The average ventricular rate was at 50 beats per minute, with epsilon wave, presence of some Premature Ventricular Complex (PVC) with a left inferior axis delay without ventricular tachycardia or conduction disorder. (Figure 5) We found 3 patterns of epsilon waves: wiggle waves, small spike waves, and smooth potential waves with the QRS duration in  $V_1$  exceeding the QRS duration in  $V_3$  by at least 25 msec. The small spike waves were divided into 2 subtypes, one upward and the other downward.



**Figure 5:24-Hour Holter Monitoring with PVC (Yellow arrows) (5a) and Epsilon Waves (5b) (Red arrows)**

The diagnosis of ARVD was made based on EKG features and structural abnormalities seen on echocardiography according to Task Force Criteria [5].

	<b>Diagnostic criteria</b>
<b>1-Morpho-functional ventricular abnormalities</b>	<p><b>MAJOR criteria</b></p> <ul style="list-style-type: none"> <li>- Akinesia associated with dilatation of the RV and global RV dysfunction PLAX RVOT=38 mm, PSAX RVOT= 39 mm, Fractional area change =19%</li> </ul> <p><b>MINOR criteria</b></p> <ul style="list-style-type: none"> <li>- Segmental akinesia of the RV</li> </ul>
<b>2-Repolarisation anomalies</b>	<p><b>Major criteria:</b></p> <ul style="list-style-type: none"> <li>- Inverted T waves in the right pre-cordium (V1, V2 and V3) or more in individuals.</li> </ul> <p><b>MINOR criteria:</b></p> <ul style="list-style-type: none"> <li>-Inverted T waves in the left precordium (V4-V6) (LEFT VENTRICLE)</li> </ul>
<b>3-Depolarisation abnormalities</b>	<p><b>Minor Criteria</b></p> <ul style="list-style-type: none"> <li>- Epsilon wave in the right precordial leads of V1 to V3</li> </ul>
<b>4-Arrhythmias</b>	<p><b>MAJOR criteria</b></p> <ul style="list-style-type: none"> <li>-Sustained ventricular tachycardia (VT) with superior axis (Negative QRS in II, III and aVF leads and positive in aVL lead).</li> </ul>

The patient was treated with sotalol 80 mg. An automatic implantable cardioverter defibrillator (ICD) was recommended to our patient for secondary prevention. Molecular genetic analysis was proposed for the patient, and a cardiological evaluation was also proposed for first-degree relatives. The patient was fine at a three-month follow-up; no sustained VT reoccurred.

**Discussion:**

Histologically, the characteristic of ARVD is the replacement of the right ventricular myocardium by fibrous and adipose tissue. The fibrous cicatricial tissue progresses from the epicardium to the endocardium and principally involves the free ventricular wall, leading to thinning of the free ventricular wall and aneurysmal dilatation. The left ventricle (LV) is less affected than the right ventricle (RV). The origin of these structural changes is genetic. Sudden death can be the first manifestation of the disease in 7-23% of cases [6]. Furthermore, the most common clinical presentations are palpitations and syncope secondary to ventricular arrhythmias induced by exercise. At advanced stages of the disease, right heart failure may develop, with or without left heart failure[7]. Electrocardiogram reveals T-wave inversion in the precordial leads (V1 to V4) and ventricular arrhythmias with a right bundle branch block pattern. Ventricular arrhythmias vary from premature ventricular complex to ventricular tachycardia or ventricular fibrillation (VF). The Doppler

echocardiography is of great help in the study of morphological abnormalities. However, the evaluation of the segmental kinetics of the RV is subjective and difficult. The presence of focal hypokinesia associated or not with parietal thinning is specific to ARVD [8]. Then, The MRI can be used to evaluate the degree of dilatation and contractile function of the RV, to look for abnormal areas of contraction as well as contraction and the presence of fibrosis.

The diagnosis of ARVD is based on a combination of arguments. A diagnostic score has been established, including major (2 points) and minor (1 point) criteria, considering EKG, paraclinical, personal, and family parameters [9]. The table (Figure 6) summarizes modified Task Force Criteria for arrhythmogenic right ventricular cardiomyopathy (ARVD). [5]

UNDER PEER REVIEW


Modified Task Force Criteria for ARVC – Diagnostic Categories Major and Minor Criteria		
Definite: 2 major OR 1 major and 2 minor, OR 4 minor criteria from different categories		
Borderline: 1 major and 1 minor, OR 3 minor criteria from different categories		
Possible: 1 major, OR 2 minor criteria from different categories		
	Major	Minor
<b>Global or regional dysfunction and structural alterations determined by echo, MRI, or RV angiography:</b>		
Echo	Regional RV akinesia, dyskinesia, or aneurysm and 1 of the following (end diastole): a) PLAX RVOT $\geq 32$ mm (PLAX/BSA $\geq 19$ mm/m <sup>2</sup> ) b) PSAX RVOT $\geq 36$ mm (PSAX/BSA $\geq 21$ mm/m <sup>2</sup> ) c) Fractional area change $\leq 33\%$	Regional RV akinesia, dyskinesia, or aneurysm and 1 of the following (end diastole): a) PLAX RVOT $\geq 29$ mm to $< 32$ mm (PLAX/BSA $\geq 16$ to $< 19$ mm/m <sup>2</sup> ) b) PSAX RVOT $\geq 32$ to $< 36$ mm (PSAX/BSA $\geq 18$ to $< 21$ mm/m <sup>2</sup> ) c) Fractional area change $> 33$ to $\leq 40\%$
MRI	Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following: a) Ratio RVEDV/BSA $\geq 110$ mL/m <sup>2</sup> (male), $\geq 100$ mL/m <sup>2</sup> (female) b) RVEF $\leq 40\%$	Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following: a) Ratio RVEDV/BSA $\geq 100$ to $< 110$ mL/m <sup>2</sup> (male), $\geq 90$ to $100$ mL/m <sup>2</sup> (female) b) RVEF $> 40$ to $\leq 45\%$
RV angiography	Regional RV akinesia, dyskinesia, or aneurysm	
<b>Tissue characterization of wall</b>		
Endomyocardial biopsy showing fibrous replacement of the RV free wall myocardium in $\geq 1$ sample, with or without fatty replacement and with:	Residual myocytes $< 60\%$ by morphometric analysis (or $< 50\%$ if estimated)	Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated)
<b>Repolarization abnormalities</b>		
ECG	Inverted T waves in right precordial leads (V <sub>1</sub> , V <sub>2</sub> , and V <sub>3</sub> ) or beyond in individuals $> 14$ years of age (in the absence of complete RBBB QRS $\geq 120$ ms)	I. Inverted T waves in leads V <sub>1</sub> and V <sub>2</sub> in individuals $> 14$ years of age (in the absence of complete RBBB) or in V <sub>4</sub> , V <sub>5</sub> , or V <sub>6</sub> . II. Inverted T waves in leads V <sub>1</sub> , V <sub>2</sub> , V <sub>3</sub> , and V <sub>4</sub> in individuals $> 14$ years of age in the presence of complete RBBB
<b>Depolarization/conduction abnormalities</b>		
ECG	Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V <sub>1</sub> to V <sub>3</sub> )	I. Late potentials by SAECG in $\geq 1$ of 3 parameters in the absence of QRS duration of $\geq 110$ ms on the standard ECG: a) Filtered QRS duration (fQRS) $\geq 114$ ms b) Duration of terminal QRS $< 40$ $\mu$ V (low-amplitude signal duration) $\geq 38$ ms c) Root-mean-square voltage of terminal 40 ms $\leq 20$ $\mu$ V II. Terminal activation duration of QRS $\geq 55$ ms measured from the nadir of the S wave to the end of the QRS, including R' in V <sub>1</sub> , V <sub>2</sub> , or V <sub>3</sub> in the absence of complete RBBB
<b>Arrhythmias</b>		
	Nonsustained or sustained VT of LBBB with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)	I. Nonsustained or sustained VT or RV outflow configuration, LBBB morphology with inferior axis (positive QRS in II, III and aVF and negative in lead aVL) or of unknown axis II. $> 500$ ventricular extrasystoles per 24 hours (Holter)
<b>Family history</b>		
	I. ARVC confirmed in a first-degree relative who meets current Task Force Criteria II. ARVC confirmed pathologically at autopsy or surgery in a first-degree relative III. Identification of a pathogenetic mutation categorized as associated or probably associated with ARVC in the patient under evaluation	I. History of ARVC in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force Criteria II. Premature sudden death ( $< 35$ years of age) due to suspected ARVC in a first-degree relative III. ARVC confirmed pathologically or by current Task Force Criteria in second-degree relative

**Figure 6: Modified Task Force Criteria for arrhythmogenic right ventricular cardiomyopathy (ARVC) showing the diagnostic categories for major and minor criteria according to the 2010 ARVC Task Force Criteria**

BSA :body surface area; ECG : electrocardiogram; echo : echocardiogram; MRI : magnetic resonance imaging; PLAX :parasternal long-axis; PSAX : parasternal short-axis; RBBB : right bundle branch block; RV: right ventricle; RVEDV: right ventricular end-diastolic volume; RVEF: right ventricular ejection fraction; RVOT: right ventricular outflow tract; SAECG: signal-averaged electrocardiogram; VT: ventricular tachycardia.

A molecular genetic analysis must be proposed to a proband in whom the diagnosis is confirmed or in case of high clinical suspicion (definite or probable diagnosis according to the task force criteria), as well as a cardiological evaluation for first-degree relatives. Then, genotyping is recommended to family members to identify genetically affected individuals in the preclinical phase[8].

The evolution is characterized by the emergence of arrhythmic events that can lead to sudden death and by an alteration of the bi-ventricular systolic function that can also lead to death by heart failure. The goal of treatment is to reduce the risk of sudden death and improve quality of life by improving the symptoms of arrhythmia and heart failure. Restricting intensive sports activities is imperative for patients with non-symptomatic mutations and patients with clinical symptoms(10). Ruwald et al. found that competitive and recreational sports participation are associated with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy (**Figure 8**)[10,11]. For a patient with ARVD and non-tolerated sustained VT, an ICD is recommended (Class I recommendation)[5]. Prophylactic anticoagulation for the primary prevention of thromboembolism based on global or regional ventricular dilatation/dysfunction, as in our patient's case, is not recommended (class III recommendation) [5].



**Figure 8:** Cumulative probability of VT/death since birth in probands with ARVC according to level of sport.[10]

### **Conclusion:**

The diagnosis of ARVC is difficult due to the lack of specific single diagnostic criteria. Once the diagnosis is made a stratification of the rhythmic and thromboembolic risk as part of prevention as well as the genetic counselling that should be proposed to the patient.

### **References:**

1. Domenico C, Guy F, Frank I. Arrhythmogenic right ventricular dysplasia cardiomyopathy. Need for an international registry. *Circulation* 2000; 101:101.
2. McKenna W, Thiene G, Nava A. The task force of the working group myocardial and pericardial disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Diagnosis of arrhythmogenic right ventricular dysplasia cardiomyopathy. *Br Heart J* 1994;71:215-8.
3. Marta de Riva et al. Twelve-Lead ECG of Ventricular Tachycardia in Structural Heart Disease. *Circulation Arrhythmia and Electrophysiology* August 2015 8 (4):951-623
4. Mike Cadogan and Robert Buttner Epsilon Wave, Feb 4, 2022 <https://litfl.com/epsilon-wave-ecg-library/>.
5. Towbin JA, and al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*. 2019 Nov;16(11):e301-e372. doi: 10.1016/j.hrthm.2019.05.007. Epub 2019 May 9. PMID: 31078652.
6. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. *Eur Heart J*. 2001;22(16):1374-450.
7. Hebert JL, Chemla D, Gerardo O et al. Angiographic right and left ventricular function in arrhythmogenic right ventricular dysplasia. *Am J Cardiol*. 2004; 93: 728-33.
8. National Diagnostic and Care Protocol (NDCP) Right Ventricular Cardiomyopathy Arrhythmogenic / Department of Chronic Diseases and Patient Support Systems September 2021.
9. Domenico Corrado, Martina Perazzolo Marra, Alessandro Zorzi, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria *International Journal of Cardiology* (2020), <https://doi.org/10.1016/j.ijcard.2020.06>.

10. Ruwald AC and al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. *Eur Heart J*. 2015 Jul 14;36(27):1735-43. doi: 10.1093/eurheartj/ehv110. Epub 2015 Apr 20. PMID: 25896080; PMCID: PMC4500847.
11. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. *J Am Coll Cardiol*. 2013;62(14):1290-7.

UNDER PEER REVIEW